论文部分内容阅读
目的:探讨盐酸氨溴索(沐舒坦)对胎鼠肺表面活性物质合成的影响。方法:选择健康清洁级妊娠的SD大鼠18只,随机分为3组,沐舒坦治疗组6只,地塞米松治疗组6只,对照组6只。各组大鼠于妊娠第16、17、18天尾静脉分别注射沐舒坦75mg/kg、地塞米松0.8mg/kg、生理盐水2ml/只。于妊娠第19天剖宫产,取出胎仔肺测定磷脂含量(肺表面活性物质主要成分为磷脂)。结果:沐舒坦治疗组肺磷脂含量为(0.72±0.06)mmol/g湿肺,地塞米松治疗组为(0.73±0.19)mmol/g湿肺,对照组为(0.62±0.09)mmol/g湿肺,沐舒坦治疗组、地塞米松治疗组与对照组差异有显著性(P<0.01),沐舒坦治疗组与地塞米松治疗组之间差异无显著性(P>0.05)。结论:沐舒坦能促进胎鼠肺表面活性物质合成,且与地塞米松作用效果相似,有可能成为临床上促胎肺成熟的药物。
Objective: To investigate the effect of Ambroxol Hydrochloride on the synthesis of pulmonary surfactant in fetal rats. Methods: Eighteen SD rats were randomly divided into 3 groups, 6 of Mucosolvan group, 6 of dexamethasone group and 6 of control group. Rats in each group were injected with Mucosolvin 75mg / kg, dexamethasone 0.8mg / kg, saline 2ml / only on the 16th, 17th, and 18th day. Cesarean section was performed on the 19th day of gestation, and the phospholipid content was measured in the fetal lung (the main component of pulmonary surfactant was phospholipid). Results: The pulmonary phlebitis content of Mucosolvan group was (0.72 ± 0.06) mmol / g wet lung, that of dexamethasone group was (0.73 ± 0.19) mmol / g wet lung and that of control group was (0.62 ± 0.09) mmol / g wet There was no significant difference between the mucosolvan treatment group and the dexamethasone treatment group (P> 0.05). CONCLUSION: Mucosolvan can promote the synthesis of pulmonary surfactant in fetal rats and has the same effect as dexamethasone, which may become clinically effective in promoting fetal lung maturation.